Patents Assigned to Children's Medical Center Corporation
  • Publication number: 20250101381
    Abstract: The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.
    Type: Application
    Filed: April 11, 2024
    Publication date: March 27, 2025
    Applicant: The Children's Medical Center Corporation
    Inventor: Paolo Fiorina
  • Patent number: 12252515
    Abstract: Provided herein are agents that bind to the lipid binding groove of Frizzled (FZD). In some embodiments, the agent is a fragment of TcdB corresponding to amino acids 1285-1804 of SEQ ID NO: 1. In some embodiments, binding of the agent to the lipid binding groove of FZD inhibits TcdB entry into cells, and/or inhibits Wnt signaling. Methods of treating Clostridium difficile infection (CDI) and methods of treating cancer are also provided.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 18, 2025
    Assignees: Children's Medical Center Corporation, The Regents of the University of California
    Inventors: Min Dong, Liang Tao, Rongsheng Jin, Peng Chen, Aina He
  • Patent number: 12252507
    Abstract: This disclosure provides methods for generating functionalized nanoswitches, as well as the functionalized nanoswitches themselves, and methods of use thereof.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: March 18, 2025
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Darren Yang, Eric M. Mulhall, Hongyu Zhao, Andrew Ward, Clinton H. Hansen, Wesley Philip Wong
  • Patent number: 12251525
    Abstract: A device for performing intervention procedures includes an elongated body having a first end and a second end. The elongated body includes a hollow tool channel extending through the elongated body from the first end to the second end. The tool channel is configured to receive an intervention tool and a length-adjusting element disposed at the first end or the second end of the elongated body. The length-adjusting element is configured to enable a length of the elongated body to be adjusted. The elongated body includes an angle-adjusting element disposed along the length of the elongated body. The angle-adjusting element is configured to enable the elongated body to be bent. The device includes an imaging system disposed at the first end or the second end of the elongated body. The imaging system includes an imaging device and an illumination device.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: March 18, 2025
    Assignee: Children's Medical Center Corporation
    Inventors: Mossab Y. Saeed, Pedro J. Del Nido, Nikolay V. Vasilyev, Niv Ad, Christopher J. Payne
  • Publication number: 20250082688
    Abstract: The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorder.
    Type: Application
    Filed: November 22, 2024
    Publication date: March 13, 2025
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Guoping Feng, Boaz Barak, Zhigang He
  • Patent number: 12241888
    Abstract: Provided herein are methods of determining whether an extracellular vesicle (EV) can cross an endothelial barrier (e.g., the blood brain barrier). In some embodiments, the EV originates from a cancer cell. In some embodiments, the cancer has a higher likelihood of metastasizing (to the brain) if the EV originating from a cancer cell is determined to be able to cross an endothelial barrier (e.g., the blood brain barrier). Thus, further provided herein are methods of determining whether a subject who has cancer is likely to develop metastatic cancer. In some embodiments, the subject is treated for the metastatic cancer accordingly.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: March 4, 2025
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Golnaz Morad
  • Publication number: 20250064836
    Abstract: Provided herein are methods of treating a Clostridioides difficile (C. difficile) infection in a subject. In some embodiments, a method of treating a C. difficile infection comprises administering an antagonist of neurogenic inflammation to a subject.
    Type: Application
    Filed: August 16, 2024
    Publication date: February 27, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Meenakshi Rao, Min Dong
  • Publication number: 20250064910
    Abstract: Technologies for the prevention and/or treatment of Salmonella infections.
    Type: Application
    Filed: November 29, 2022
    Publication date: February 27, 2025
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard MALLEY, Fan ZHANG, Yingjie LU
  • Publication number: 20250064983
    Abstract: The invention of the disclosure features Ca2+-calmodulin dependent kinase II (CaMKII) inhibitory multimeric polypeptides polynucleotides encoding such polypeptide, and methods of using the same for the treatment of cardiac diseases (e.g., catecholaminergic polymorphic ventricular tachycardia (CPVT) or atrial fibrillation (AF)).
    Type: Application
    Filed: November 15, 2024
    Publication date: February 27, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Vassilios J. Bezzerides, William J. Pu, Sofia M. De La Serna Buzon
  • Publication number: 20250066429
    Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
    Type: Application
    Filed: April 3, 2024
    Publication date: February 27, 2025
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Malley, Yingjie Lu, Fan Zhang
  • Publication number: 20250057930
    Abstract: The invention features compositions and methods for treating anaplastic lymphoma kinase (ALK)-rearranged neoplasias including Non-Small Cell Lung Cancers (NSCLCs). The methods involve administering to a subject ALK peptides and/or polynucleotides encoding the ALK peptides, optionally in combination with an immune checkpoint inhibitor (ICI) and/or an ALK tyrosine kinase inhibitor (TKI).
    Type: Application
    Filed: November 4, 2024
    Publication date: February 20, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Roberto Chiarle, Rafael Blasco-Patino
  • Publication number: 20250059544
    Abstract: Provided herein are antisense oligonucleotides for use in targeting SARS-CoV-2. Also provided herein are compositions comprising such oligonucleotides and methods for administering the oligonucleotides or compositions thereof to a subject for the purpose of treating or preventing a SARS-CoV-2 infection.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 20, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Hao Wu, Longfei Wang, Setu M. Vora
  • Patent number: 12229873
    Abstract: The invention features a prospective respiratory motion compensation technique for cardiovascular magnetic resonance imaging of the whole-heart of a free-breathing subject.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: February 18, 2025
    Assignee: The Children's Medical Center Corporation
    Inventors: Mehdi H. Moghari, Andrew J. Powell, Tal Geva
  • Publication number: 20250049711
    Abstract: Provided herein are compositions comprising compounds of Formula (I), and salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, and isotopically enriched derivatives thereof; for example, in the form of a particle (e.g., liposome). Also provided are methods, uses, pharmaceutical compositions, and kits involving the compounds and/or compositions described herein, for methods for delivering an agent described herein (e.g., therapeutic agent, diagnostic agent), or for treating and/or preventing a disease in a subject, and methods of synthesizing these compositions.
    Type: Application
    Filed: December 6, 2022
    Publication date: February 13, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Yang Li
  • Publication number: 20250049839
    Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
    Type: Application
    Filed: October 31, 2024
    Publication date: February 13, 2025
    Applicants: Children's Medical Center Corporation, Politecnico di Milano, Dana-Farber Cancer Institute, Inc.
    Inventors: Marco Peviani, Alessandra Biffi, Davide Moscatelli, Umberto Capasso Palmiero, Renato Auriemma, Mattia Sponchioni, Letterio Salvatore Politi
  • Publication number: 20250042974
    Abstract: Described herein are a ApoA1 and ApoM (A1M) fusion proteins, lipidated A1M fusion proteins, nanoparticles comprising AM1 fusion proteins, and methods of use thereof for treatment of vascular and inflammatory disorders.
    Type: Application
    Filed: September 30, 2022
    Publication date: February 6, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman
  • Publication number: 20250041278
    Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described for proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease, in a subject in need thereof. Using the compound as a vaccine adjuvant enables effective immunization in vulnerable populations.
    Type: Application
    Filed: September 29, 2022
    Publication date: February 6, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: David J. Dowling, Ofer Levy, Simon D. van Haren, Katherine Chew, Dheeraj Soni, Maria De Leon
  • Patent number: 12216186
    Abstract: Scan time in diffusion-relaxation magnetic resonance imaging (“MRI”) is reduced by implementing time-division multiplexing (“TDM”). In general, time-shifted radio frequency (“RF”) pulses are used to excite two or more imaging volumes. These RF pulses are applied to induce separate echoes for each slice. Diffusion MRI data can thus be acquired with different echo times, or alternatively with the same echo time, in significantly reduced overall scan time. Multidimensional correlations between diffusion and relaxation parameters can be estimated from the resulting data.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: February 4, 2025
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Lipeng Ning, Yogesh Rathi, Yang Ji, Borjan Gagoski
  • Patent number: 12215351
    Abstract: Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBF? inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 4, 2025
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Joseph Mandelbaum
  • Publication number: 20250034568
    Abstract: The technologies as described herein relate to compositions and methods for the treatment of hemoglobinopathies by increasing fetal hemoglobin in a subject.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 30, 2025
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE
    Inventors: David A. WILLIAMS, Daniel E. BAUER, Christian BRENDEL